The evolution of locoregional therapy in the last 2 decades has changed the perpective in the clinical management of patients affected by peritoneal surface malignancies from mere palliation to possible cure . Results from Phase II studies testing the combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemoperfusion (HIPEC) in the treatment of peritoneal carcinomatosis (PC) of various origins have been encouraging . In previous papers, we reported 5-year overall survival rates of 97% and 57%, respectively, for patients with pseudomyxoma peritonei  and malignant peritoneal mesothelioma [4-5] treated with CRS and HIPEC. Other authors have reported 5-year overall survival rates of 63.4% and 19%, respectively, in ovarian  and colorectal cancer . Moreover, results of a phase III trial have confirmed the superiority of CRS and HIPEC in the treatment of patients with PC from colorectal cancer over other standard surgical and/or systemic chemotherapy (CT) modalities .
ASJC Scopus subject areas